El Segundo (1)

NonHodgkin's Lymphoma Refractory (1)

Not yet recruiting (1)

phase 1 (1)

ImmunityBio, Inc. (1)

cd19t-hank suspension (1)

cyclophosphamide (1)

fludarabine (1)

n803 (1)

rituximab (1)

biological (1)

drug (1)

Industry (1)

Interventional (1)

nonhodgkin's lymphoma refractory

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Not yet recruiting

Nov 9, 2022